Arca Biopharma | ABIO - Assets


Arca Biopharma reported $504.48M in Assets for its fiscal quarter ending in March of 2026.





Assets Change Date
Alterity Therapeutics Limited AUD 37.98M 15.78M Dec/2025
Amgen USD 92.5B 1.92B Mar/2026
Arca Biopharma USD 504.48M 15.86M Mar/2026
Biogen USD 29.48B 43.6M Mar/2026
Brainstorm Cell Therapeutics USD 755K 267K Mar/2026
Bristol-Myers Squibb USD 86.48B 3.56B Mar/2026
Capricor Therapeutics USD 326.28M 29.66M Mar/2026
Cipla INR 424.96B 23.32B Mar/2026
Clal Biotechnology ILS 158.39M 24.3M Dec/2023
Compugen USD 156.57M 58.73M Dec/2025
CSL USD 37.9B 1.5B Dec/2025
Cytokinetics USD 1.27B 151.06M Mar/2026
Daiichi Sankyo JPY 3.82T 252.52B Dec/2025
Gilead Sciences USD 56.28B 2.74B Mar/2026
GlaxoSmithKline GBP 62.87B 1.75B Mar/2026
Grifols EUR 23.15B 142.7M Dec/2025
Laboratory Of America USD 19.09B 694.4M Mar/2026
Myriad Genetics USD 673.7M 32.9M Mar/2026
Otsuka Holdings JPY 4.21T 11.63B Mar/2026
Pfizer USD 207.62B 542M Mar/2026
United Therapeutics USD 6.71B 1.17B Mar/2026